Nath Bio-Genes Q1 FY27: Revenue up 15% at Rs 322.84 Cr, PAT Rs 32.66 Cr

Exceptional itemResults View source PDF Explain this filing

NATHBIOGEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹160.11

prior close

₹162.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%+0.8% vs market

Other Agricultural Products peers, median of 57sector+0.3%-0.1% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 0.1 pts less than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.3

10m

+4.6

15m

+4.2

30m

+1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2-0.6+0.8+0.3-0.1

Next day

-0.1+0.5-0.6+0.0-0.1

-0.7+1.9-2.5+0.0-0.7

+3.0+2.3+0.7+0.9+2.1

+2.5+3.6-1.2+0.4+2.1

-0.1+4.0-4.1+0.3-0.4

-1.8+4.0-5.8+1.7-3.5

15d

-2.7+4.9-7.6-2.9+0.2

-0.8+5.9-6.7-1.4+0.7

-11.1+4.8-15.9-0.7-10.4

-18.2pendingpending-3.8-14.4

UpDownMarket · Nifty Microcap 250Sector · Other Agricultural Products peers, median of 57Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone revenue rose 15.2% YoY to Rs 32,284 lakhs from Rs 28,017 lakhs. Net profit grew 11.8% to Rs 3,266 lakhs from Rs 2,921 lakhs. EPS at Rs 17.18 versus Rs 15.37. Consolidated revenue Rs 32,840 lakhs and PAT Rs 3,226 lakhs. Exceptional items income of about Rs 120 lakhs included. Auditor issued an unqualified review report. 33rd AGM scheduled for 24 September 2026 via video conference.

Likely market impact

Solid topline growth with steady profitability. Healthy quarterly performance for shareholders.